Dr. Nick Goeden and Dr. Nick Flytzanis – “the Nicks,” as many of their colleagues call them – have a lot in common. They’re both co-founders and leaders at Capsida Biotherapeutics. They’re both 35 years old. And, this month, they were both named to the 2022 Endpoints “20 Under 40” list. This annual honor, selected from hundreds of quality nominations, highlights the next generation of biotech leaders. Dr. Goeden serves as Chief Technology Officer of Capsida, while Dr. Flytzanis is the company’s Chief Scientific Officer. From their beginnings at Caltech to how they’re growing Capsida into an innovative AAV gene therapy company, read more about these leaders here.